On May, 10 Cytori Therapeutics, Inc. (CYTX) EPS Estimated At $-0.06

April 17, 2018 - By Darrel Chase

Cytori Therapeutics, Inc. (NASDAQ:CYTX) Corporate Logo

Cytori Therapeutics, Inc. (NASDAQ:CYTX)’s quarterly earnings will be published On May, 10., according to Faxor. Last year’s earnings per share was $-0.26, while now analysts expect change of 76.92 % up from current $-0.06 earnings per share. Wall Street sees -40.00 % EPS growth as of May, 10. On during the last trading session the stock decreased $0.002 or 0.55%, reaching $0.273.Cytori Therapeutics, Inc. has volume of 606,410 shares. Since April 17, 2017 CYTX has declined 82.57% and is downtrending. CYTX underperformed the S&P500 by 94.12%.

Cytori Therapeutics, Inc. (NASDAQ:CYTX) Ratings Coverage

Total analysts of 3 have positions in Cytori Therap (NASDAQ:CYTX) as follows: 2 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 67%. Since November 7, 2017 according to StockzIntelligence Inc Cytori Therap has 3 analyst reports. On Thursday, February 22 the rating was maintained by Laidlaw with “Buy”. On Friday, March 9 the stock has “Buy” rating by Maxim Group.

Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions.The firm is worth $16.82 million. The firm primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma.Currently it has negative earnings. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments.

Cytori Therapeutics, Inc. (NASDAQ:CYTX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.